Skip to main content
Erschienen in: Tumor Biology 10/2014

01.10.2014 | Research Article

STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α

verfasst von: Chi Zhang, Xi Yang, Qu Zhang, Qing Guo, Jia He, Qin Qin, Hongcheng Zhu, Jia Liu, Liangliang Zhan, Jing Lu, Zheming Liu, Liping Xu, Jianxin Ma, Shengbin Dai, Hongyan Cheng, Xinchen Sun

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Radiotherapy is the main therapy for inoperable and locally advanced esophageal squamous cell carcinoma (ESCC). However, radioresistance in ESCC remains a challenge. The aim of this study is to investigate the radiosensitizing effects of STAT3 inhibitor NSC74859 on ESCC and explore the underlying mechanisms. ECA109 and TE13 cells were exposed to hypoxia, and treated with NSC74859 or radiation, alone or in combination. Cell proliferation, survival, apoptosis, and double-stranded DNA breaks (DSBs) were examined. Nude mice model of ECA109 xenograft was treated with radiation and/or NSC74859. The levels of STAT3, p-STAT3, HIF-1α, and VEGF were detected by Western blot analysis. NSC74859 efficiently radiosensitized ESCC cells and xenografts in nude mice, and inhibited hypoxia-/radiation-induced activation of STAT3 and upregulation of HIF-1α and VEGF expression. NSC74859 confers radiosensitivity in ESCC via the inhibition of STAT3 activation and the downregulation of HIF-1α and VEGF expression. NSC74859 may become a promising radiosensitizer for ESCC radiotherapy.
Literatur
1.
3.
Zurück zum Zitat Albini ATF, Li VW, Noonan DM, et al. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9:498–509.CrossRefPubMed Albini ATF, Li VW, Noonan DM, et al. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9:498–509.CrossRefPubMed
4.
Zurück zum Zitat Zhu GH, Huang C, Feng ZZ, Lv XH, Qiu ZJ. Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Dig Dis Sci. 2013;58:3503–15.CrossRefPubMed Zhu GH, Huang C, Feng ZZ, Lv XH, Qiu ZJ. Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Dig Dis Sci. 2013;58:3503–15.CrossRefPubMed
5.
Zurück zum Zitat Niu GBJ, Deng J, Ma Y, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008;6:1099–105.PubMedCentralCrossRefPubMed Niu GBJ, Deng J, Ma Y, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008;6:1099–105.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Jung JELH, Cho IH, Chung DH, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005;19:1296–8.PubMed Jung JELH, Cho IH, Chung DH, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005;19:1296–8.PubMed
7.
Zurück zum Zitat Lin LHB, Li PK, Ball S, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010;12:39–50.PubMedCentralCrossRefPubMed Lin LHB, Li PK, Ball S, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010;12:39–50.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Wei C, Xuning S, Xuefeng X, et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 2012;32(1):70–77. Wei C, Xuning S, Xuefeng X, et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 2012;32(1):70–77.
9.
Zurück zum Zitat Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010;79(10):1398–409. 15.PubMedCentralCrossRefPubMed Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010;79(10):1398–409. 15.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Siddiquee KZS, Guida WC, Blaskovich MA, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18):7391–6.PubMedCentralCrossRefPubMed Siddiquee KZS, Guida WC, Blaskovich MA, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18):7391–6.PubMedCentralCrossRefPubMed
11.
12.
Zurück zum Zitat Dal MM. Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(6):593–612.CrossRef Dal MM. Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(6):593–612.CrossRef
13.
Zurück zum Zitat Yang X, Yang B, Cai J, et al. Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo. Cancer Biol Ther. 2013;14(11):1068–73.PubMedCentralCrossRefPubMed Yang X, Yang B, Cai J, et al. Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo. Cancer Biol Ther. 2013;14(11):1068–73.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Zhang C, Yang X, Zhang Q, et al. Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1α expression. Acta Otolaryngol. 2014;134(2):185–92.CrossRefPubMed Zhang C, Yang X, Zhang Q, et al. Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1α expression. Acta Otolaryngol. 2014;134(2):185–92.CrossRefPubMed
15.
Zurück zum Zitat Zhang Q, Zhang C, Yang X, et al. Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer. Diagn Pathol. 2014;9(1):98. 27.PubMedCentralCrossRefPubMed Zhang Q, Zhang C, Yang X, et al. Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer. Diagn Pathol. 2014;9(1):98. 27.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21:7611–8.CrossRefPubMed Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21:7611–8.CrossRefPubMed
17.
Zurück zum Zitat Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.CrossRefPubMed Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.CrossRefPubMed
18.
Zurück zum Zitat Timme S, Ihde S, Fichter CD, et al. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. Oncogene. 2013. doi:10.1038/onc.2013.298.PubMed Timme S, Ihde S, Fichter CD, et al. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. Oncogene. 2013. doi:10.​1038/​onc.​2013.​298.PubMed
19.
Zurück zum Zitat You ZXD, Ji J, et al. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clin Transl Oncol. 2012;14(2):143–9.CrossRefPubMed You ZXD, Ji J, et al. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clin Transl Oncol. 2012;14(2):143–9.CrossRefPubMed
20.
Zurück zum Zitat Pan Y, Zhou F, Zhang R, et al. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS ONE. 2013;8(1):e54565.PubMedCentralCrossRefPubMed Pan Y, Zhou F, Zhang R, et al. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS ONE. 2013;8(1):e54565.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Adachi M, Cui C, Dodge CT, et al. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012;48:1220–6.PubMedCentralCrossRefPubMed Adachi M, Cui C, Dodge CT, et al. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012;48:1220–6.PubMedCentralCrossRefPubMed
Metadaten
Titel
STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α
verfasst von
Chi Zhang
Xi Yang
Qu Zhang
Qing Guo
Jia He
Qin Qin
Hongcheng Zhu
Jia Liu
Liangliang Zhan
Jing Lu
Zheming Liu
Liping Xu
Jianxin Ma
Shengbin Dai
Hongyan Cheng
Xinchen Sun
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2207-3

Weitere Artikel der Ausgabe 10/2014

Tumor Biology 10/2014 Zur Ausgabe

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.